• ac4C-Modified lncRNA Gm26917 Regulates Translation in FGSCs

  2026-06-01

  This study uncovers a novel mechanism in which N4-acetylcytidine (ac4C) modification of lncRNA Gm26917 is essential for maintaining female germline stem cell (FGSC) translation efficiency and cell fate. By mapping molecular interactions via advanced sequencing, the authors delineate an ac4C–EEF1A1–Rpl10 axis, highlighting new targets for fertility and stem cell research.

• Gallein: Applied Protocols for G Protein βγ Subunit Inhibiti

  2026-05-31

  Gallein, a selective G protein βγ subunit inhibitor from APExBIO, enables precise modulation of GPCR pathways in cancer, immune, and cardiometabolic research. This guide details step-by-step workflows, practical troubleshooting, and integration with emerging metabolic models, helping researchers unlock reproducible and translational results.

• Mutational Drivers and Drug Resistance in Multiple Myeloma C

  2026-05-30

  This study delivers the first comprehensive exome-wide analysis of human multiple myeloma cell lines, revealing both established and novel mutational drivers implicated in tumor progression and drug resistance. These findings provide a critical framework for selecting and interpreting preclinical models in hematological malignancy research, directly informing the design of targeted therapeutic strategies.

• IPA-3: Selective Pak1 Inhibition for Advanced Kinase Assays

  2026-05-29

  IPA-3, a non-ATP-competitive Pak1 inhibitor, empowers researchers to dissect signaling pathways with exceptional selectivity in kinase and cell motility assays. This article delivers practical workflow enhancements, troubleshooting strategies, and research-driven insights for maximizing IPA-3's impact in cancer biology and neuroinflammation studies.

• Dasatinib (BMS-354825): Precision Tools for Decoding Kinase

  2026-05-29

  Explore how Dasatinib (BMS-354825) transforms kinase research by enabling precise dissection of Src and Bcr-Abl signaling in cancer models. This article uniquely connects molecular pharmacology with advanced assay design for chronic myeloid leukemia and EMT studies.

• Phosphatase Inhibitor Cocktail 3: Precision in Phosphoprotei

  2026-05-28

  Phosphatase Inhibitor Cocktail 3 (100X in DMSO) from APExBIO stands out for its robust and comprehensive inhibition of serine/threonine phosphatases, making it essential for researchers requiring reliable protein phosphorylation preservation. This article bridges recent mechanistic cell signaling advances with practical experimental workflows, troubleshooting, and actionable protocol guidelines.

• Berberine Hydrochloride in Metabolic and Inflammation Resear

  2026-05-28

  Berberine hydrochloride offers a unique intersection of metabolic modulation and anti-inflammatory action, making it essential for advanced disease modeling. This guide distills best practices for experimental setup, protocol optimization, and troubleshooting, translating recent research breakthroughs into actionable lab strategies.

• TUNEL Apoptosis Detection Kit (DAB): DNA Fragmentation in Ap

  2026-05-27

  The TUNEL Apoptosis Detection Kit (DAB) enables precise identification of DNA fragmentation during apoptosis in tissue sections and cultured cells. Using the TdT enzyme and HRP-conjugated detection, this kit provides clear, reproducible results for programmed cell death research. It is widely applied in mechanistic and translational apoptosis studies.

• Adipose-Neural Axis Drives Cardiac Arrhythmias via Leptin-NP

  2026-05-27

  Fan et al. (2024) introduce a stem cell-based coculture model revealing that the adipose-neural axis, through leptin and neuropeptide Y (NPY) signaling, critically contributes to epicardial adipose tissue (EAT)-related cardiac arrhythmias. This mechanistic insight identifies new molecular targets for potential therapeutic intervention in arrhythmia and refines approaches to experimental disease modeling.

• Dual-Action p38α MAPK Inhibitors Promote Dephosphorylation

  2026-05-26

  The referenced study uncovers that certain kinase inhibitors, including selective agents targeting p38α MAPK, not only block kinase activity but also accelerate phosphatase-mediated dephosphorylation by stabilizing a unique activation loop conformation. This dual-action mechanism opens new avenues for increasing inhibitor specificity and potency, with implications for inflammation and disease modeling.

• Lopinavir (ABT-378): Applied HIV Protease Inhibitor Workflow

  2026-05-26

  Lopinavir (ABT-378) delivers unmatched potency for HIV protease inhibition—even in serum-rich environments—and demonstrates cross-pathogen utility as a rapid-response antiviral, as validated by recent FDA-approved compound screens. This guide translates the latest research and supplier-verified workflows into actionable protocols, troubleshooting tips, and future-facing insights for advanced HIV and emerging virus research.

• Genotyping Kit for Target Alleles: Reliable DNA Prep in Dive

  2026-05-25

  This article offers a scenario-driven, evidence-based exploration of how the Genotyping Kit for target alleles of insects, tissues, fishes and cells (SKU K1026) addresses persistent laboratory challenges in genomic DNA preparation and PCR. Through real-world Q&A, we demonstrate the kit’s impact on sample integrity, assay reliability, and workflow efficiency—empowering researchers engaged in molecular biology genotyping research.

• Mitoxantrone HCl: Precision Allostery, DNA Damage, and ER Ta

  2026-05-25

  Explore how Mitoxantrone HCl, a leading DNA topoisomerase II inhibitor, uniquely bridges DNA damage and allosteric estrogen receptor degradation for advanced oncology and stem cell research. This in-depth analysis offers practical guidance beyond classic protocols.

• LY364947: Precision TGF-β Type I Receptor Kinase Inhibitor f

  2026-05-24

  LY364947 is a benchmark TGF-β type I receptor kinase inhibitor that empowers researchers to dissect and modulate epithelial-mesenchymal transition (EMT) and TGF-β signaling with unmatched specificity. Applied protocols, troubleshooting insights, and integration with advanced cancer models make it a cornerstone for preclinical research in fibrosis, oncology, and retinal degeneration.

• Polyvalent Vaccination Targets Tumor Microbiome to Prevent M

  2026-05-23

  Kang et al. present a polyvalent vaccine that selectively eliminates tumor-associated bacteria, reducing breast cancer metastasis in preclinical models. This research highlights the therapeutic potential of modulating the intratumoral microbiome and provides a new immunological approach to cancer metastasis prevention.

15542 records 1/1037 page Next 12345 下5页 Last page